Angola vs Bahrain: Access to anti-retroviral drugs, male
Angola
52.0%
in 2024
Bahrain
53.0%
in 2024
Angola rank
113th
Bahrain rank
112th
Access to anti-retroviral drugs, male over time
- Angola
- Bahrain
How they compare
Bahrain currently reports 53.0% against 52.0% in Angola, a difference of 1.0%.
The two have swapped places 2 times across 25 shared years of data; in 2000 it was Bahrain ahead.
Angola ranks 113th and Bahrain ranks 112th of 141 countries.
Bahrain has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Angola | Bahrain | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 2.6% | 9.9% | 7.3% | Bahrain |
| 2010s | 23.6% | 30.1% | 6.5% | Bahrain |
| 2020s | 43.2% | 52.2% | 9.0% | Bahrain |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Angola or Bahrain?
- Bahrain, at 53.0% against 52.0% in Angola as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Angola and Bahrain?
- 1.0%, with Bahrain ahead.
- How many years of comparable data are there for Angola and Bahrain?
- 25 years are reported by both, from 2000 to 2024.
- How do Angola and Bahrain rank globally for access to anti-retroviral drugs, male?
- Angola ranks 113th and Bahrain ranks 112th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.